Advertisement

Digestive Diseases and Sciences

, Volume 62, Issue 6, pp 1615–1620 | Cite as

Low-Dose Cannabidiol Is Safe but Not Effective in the Treatment for Crohn’s Disease, a Randomized Controlled Trial

  • Timna Naftali
  • Refael Mechulam
  • Amir Marii
  • Gila Gabay
  • Asaf Stein
  • Miriam Bronshtain
  • Ido Laish
  • Fabiana Benjaminov
  • Fred M. Konikoff
Original Article

Abstract

Background

Cannabidiol (CBD) is an anti-inflammatory cannabinoid shown to be beneficial in a mouse model of IBD. Lacking any central effect, cannabidiol is an attractive option for treating inflammatory diseases.

Aim

To assess the effects of cannabidiol on Crohn’s disease in a randomized placebo-controlled trial.

Patients and Methods

Twenty patients aged 18–75 years with a Crohn’s disease activity index (CDAI) >200 were randomized to receive oral (10 mg) CBD or placebo twice daily. Patients did not respond to standard treatment with steroids (11 patients), thiopurines (14), or TNF antagonists (11). Disease activity and laboratory parameters were assessed during 8 weeks of treatment and 2 weeks thereafter. Other medical treatment remained unchanged.

Results

Of 20 patients recruited 19 completed the study. Their mean age was 39 ± 15, and 11 were males. The average CDAI before cannabidiol consumption was 337 ± 108 and 308 ± 96 (p = NS) in the CBD and placebo groups, respectively. After 8 weeks of treatment, the index was 220 ± 122 and 216 ± 121 in the CBD and placebo groups, respectively (p = NS). Hemoglobin, albumin, and kidney and liver function tests remained unchanged. No side effects were observed.

Conclusion

In this study of moderately active Crohn’s disease, CBD was safe but had no beneficial effects. This could be due to lack of effect of CBD on Crohn’s disease, but could also be due to the small dose of CBD, the small number of patients in the study, or the lack of the necessary synergism with other cannabinoids. Further investigation is warranted.

ClinicalTrials.gov

NCT01037322.

Keywords

Cannabidiol Cannabis Crohn’s disease Inflammatory bowel disease 

Notes

Compliance with ethical standards

Conflict of interest

The authors declare that they have no conflict of interest.

References

  1. 1.
    Pariente B, Laharie D. Review article: why, when and how to de-escalate therapy in inflammatory bowel diseases. Aliment Pharmacol Ther. 2014;40:338–353. doi: 10.1111/apt.12838.CrossRefPubMedGoogle Scholar
  2. 2.
    Massa F, Storr M, Lutz B. The endocannabinoid system in the physiology and pathophysiology of the gastrointestinal tract. J Mol Med (Berl). 2005;83:944–954.CrossRefGoogle Scholar
  3. 3.
    Izzo AA, Camilleri M. Emerging role of cannabinoids in gastrointestinal and liver diseases: basic and clinical aspects. Gut. 2008;57:1140–1155.CrossRefPubMedGoogle Scholar
  4. 4.
    Lal S, Prasad N, Ryan M, et al. Cannabis use amongst patients with inflammatory bowel disease. Eur J Gastroenterol Hepatol. 2011;23:891–896.CrossRefPubMedGoogle Scholar
  5. 5.
    Naftali T, Lev LB, Yablecovitch D, Half E, Konikoff FM. Treatment of Crohn’s disease with cannabis: an observational study. [Erratum appears in Isr Med Assoc J. 2011;13:582 Note: Yablekovitz, Doron (corrected to Yablecovitch, Doron)]. Isr Med Assoc J IMAJ. 2011;13:455–458.Google Scholar
  6. 6.
    Weiss A, Friedenberg F. Patterns of cannabis use in patients with inflammatory bowel disease: a population based analysis. Drug Alcohol Depend. 2015;156:84–89.CrossRefPubMedGoogle Scholar
  7. 7.
    Moore THM, Zammit S, Lingford-hughes A, et al. Cannabis use and risk of psychotic or affective mental health outcomes: a systematic review. Lancet. 2007;370:319–328.CrossRefPubMedGoogle Scholar
  8. 8.
    Zhang MW, Ho RCM. The cannabis dilemma: a review of its associated risks and clinical efficacy. J Addict. 2015;2015:1–6.CrossRefGoogle Scholar
  9. 9.
    Gaoni Y, Mechoulam R. The isolation and structure of delta-1-tetrahydrocannabinol and other neutral cannabinoids from hashish. J Am Chem Soc. 1971;93:217–224.CrossRefPubMedGoogle Scholar
  10. 10.
    Mechoulam R, Peters M, Murillo-Rodriguez E, Hanus LO. Cannabidiol—recent advances. Chem Biodivers. 2007;4:1678–1692.CrossRefPubMedGoogle Scholar
  11. 11.
    Zuardi AW. Cannabidiol: from an inactive cannabinoid to a drug with wide spectrum of action Canabidiol: de um canabinóide inativo a uma droga com amplo espectro de ação. Rev Bras Psiquiar. 2008;30:271–280.CrossRefGoogle Scholar
  12. 12.
    Esposito G, De Filippis D, Cirillo C, et al. Cannabidiol in inflammatory bowel diseases: a brief overview. Phyther Res. 2012;2013:633–636.Google Scholar
  13. 13.
    Burstein S. Cannabidiol (CBD) and its analogs: a review of their effects on inflammation. Bioorg Med Chem. 2015;23:1377–1385.CrossRefPubMedGoogle Scholar
  14. 14.
    Sacerdote P, Martucci C, Vaccani A, et al. The nonpsychoactive component of marijuana cannabidiol modulates chemotaxis and IL-10 and IL-12 production of murine macrophages both in vivo and in vitro. J Neuroimmunol. 2005;159:97–105.CrossRefPubMedGoogle Scholar
  15. 15.
    Kozela E, Pietr M, Juknat A, Rimmerman N, Levy R, Vogel Z. Cannabinoids delta(9)-tetrahydrocannabinol and cannabidiol differentially inhibit the lipopolysaccharide-activated NF-kappaB and interferon-beta/STAT proinflammatory pathways in BV-2 microglial cells. J Biol Chem. 2010;285:1616–1626.CrossRefPubMedGoogle Scholar
  16. 16.
    Capasso R, Borrelli F, Aviello G, et al. Cannabidiol, extracted from Cannabis sativa, selectively inhibits inflammatory hypermotility in mice. Br J Pharmacol. 2008;154:1001–1008.CrossRefPubMedPubMedCentralGoogle Scholar
  17. 17.
    Schicho R, Storr M. Topical and systemic cannabidiol improves trinitrobenzene sulfonic acid colitis in mice. Pharmacology. 2012;89:149–155.CrossRefPubMedPubMedCentralGoogle Scholar
  18. 18.
    Pertwee RG. The diverse CB1 and CB2 receptor pharmacology of three plant cannabinoids: delta9-tetrahydrocannabinol, cannabidiol and delta9-tetrahydrocannabivarin. Br J Pharmacol. 2008;153:199–215.CrossRefPubMedGoogle Scholar
  19. 19.
    Izzo AA, Borrelli F, Capasso R, Di Marzo V, Mechoulam R. Non-psychotropic plant cannabinoids: new therapeutic opportunities from an ancient herb. Trends Pharmacol Sci. 2009;30:515–527.CrossRefPubMedGoogle Scholar
  20. 20.
    De Filippis D, Esposito G, Cirillo C, et al. Cannabidiol reduces intestinal inflammation through the control of neuroimmune axis. PLoS ONE. 2011;6:e28159.CrossRefPubMedPubMedCentralGoogle Scholar
  21. 21.
    Katsidoni V, Kastellakis A, Panagis G. Biphasic effects of Δ9-tetrahydrocannabinol on brain stimulation reward and motor activity. Int J Neuropsychopharmacol. 2013;16:2273–2284.CrossRefPubMedGoogle Scholar
  22. 22.
    Fasinu PS, Phillips S, Elsohly MA, Walker LA. Current status and prospects for cannabidiol preparations as new therapeutic agents. Pharmacotherapy. 2016;36:781–796.CrossRefPubMedGoogle Scholar
  23. 23.
    Wright MJ, Vandewater SA, Taffe MA. Cannabidiol attenuates deficits of visuospatial associative memory induced by delta9tetrahydrocannabinol. Br J Pharmacol. 2013;170:1365–1373.CrossRefPubMedPubMedCentralGoogle Scholar
  24. 24.
    Kwiatkowska M, Parker LA, Burton P, Mechoulam R. A comparative analysis of the potential of cannabinoids and ondansetron to suppress cisplatin-induced emesis in the Suncus murinus (house musk shrew). Psychopharmacology. 2004;174:254–259.CrossRefPubMedGoogle Scholar
  25. 25.
    Hawksworth G, McArdle K. Metabolism and pharmacokinetics of cannabinoids. In: Guy GC, Robson PJ, Whittle BA, eds. The Medicinal Uses of Cannabis and Cannabinoids. London: London Pharmaceutical Press; 2004:205–228.Google Scholar
  26. 26.
    Kang M, Ragan BG, Park J-H. Issues in outcomes research: an overview of randomization techniques for clinical trials. J Athl Train. 2008;43:215–221.CrossRefPubMedPubMedCentralGoogle Scholar
  27. 27.
    Russo EB. Taming THC: potential cannabis synergy and phytocannabinoid–terpenoid entourage effects. Br J Pharmacol. 2011;163:1344–1364.CrossRefPubMedPubMedCentralGoogle Scholar
  28. 28.
    Leo A, Russo E, Elia M. Cannabidiol and epilepsy: rationale and therapeutic potential. Pharmacol Res. 2016;107:85–92.CrossRefPubMedGoogle Scholar
  29. 29.
    Kumar RN, Chambers WA, Pertwee RG. Pharmacological actions and therapeutic uses of cannabis and cannabinoids. Anaesthesia. 2008;56:1059–1068.CrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media New York 2017

Authors and Affiliations

  1. 1.Department of GastroenterologyMeir Medical CenterKfar SabaIsrael
  2. 2.Sackler School of MedicineTel Aviv UniversityTel AvivIsrael
  3. 3.School of Pharmacology, Hadassa Medical SchoolHebrew University of JerusalemJerusalemIsrael
  4. 4.Faculty of Pharmacology, School of MedicineHebrew UniversityEin Karem, JerusalemIsrael
  5. 5.Hilel Yafe Medical CenterHaderaIsrael

Personalised recommendations